Skip to content

J. Veys Pharma: what changed

BE 0804.880.858NACE 47.730, Retail sale of pharmaceutical productsOther company

Position among the sector peers

What moved between 2024 and 2025

Net result for the year
€15,149
2024 · €62,448-€47,299
Equity
€81,597
2024 · €66,448+€15,149
Cash
€51,831
2024 · €27,117+€24,714
Balance sheet total
€94,994
2024 · €75,327+€19,667

Largest movements

2024 to 2025
Assets
  • Cash +€24,714

    up €24,714 (+91.1%), from €27,117 to €51,831

    mainly Net result for the year (+€15,149) and Receivables within one year (+€4,299)

  • Receivables within one year -€4,299

    down €4,299 (-10.0%), from €43,143 to €38,844

    of which Other amounts receivable: -€4,084

  • Tangible fixed assets -€1,592

    down €1,592 (-31.4%), from €5,068 to €3,476

    of which Plant, machinery and equipment: -€1,246

Equity and liabilities
  • Reserves +€15,149

    first reported in 2025, at €15,149

  • Trade debts +€3,084

    up €3,084 (+1,071%), from €288 to €3,372

  • Tax, wage and social debts +€1,433

    up €1,433 (+16.7%), from €8,591 to €10,025

Income statement
  • Gross operating margin -€58,909

    down €58,909 (-71.9%), from €81,906 to €22,997

  • Taxes -€10,059

    down €10,059 (-56.8%), from €17,708 to €7,649

  • Financial income +€2,122

    up €2,122 (+7,633%), from €28 to €2,150

Change in the result, 2024 to 2025

effect on the result

For each income-statement line you see the change as its effect on the result.

Result 2024 €62,448
Gross operating margin -€58,909
Depreciation -€314
Other operating charges -€380
Financial income +€2,122
Financial charges +€122
Taxes +€10,059
Result 2025 €15,149
raises the resultlowers the result

Derived cash bridge

cash 2024 to 2025

The bridge is derived from the 2024 and 2025 balance sheets and the 2025 result. There is no filed cash-flow statement. You see where the money came from and where it went.

From operations +€24,714
Investment €0
Financing €0
Cash 2024 €27,117
Net result for the year +€15,149
Depreciation +€1,592
Receivables within one year +€4,299
Deferred charges and accrued income -€844
Trade debts +€3,084
Tax, wage and social debts +€1,433
Cash 2025 €51,831
brings cash intakes cash out
Every line side by side 36 lines
Line Code 2024 2025 Change %
Total assets 20/58 €75,327 €94,994 +€19,667 +26.1%
Fixed assets 21/28 €5,068 €3,476 -€1,592 -31.4%
Tangible fixed assets 22/27 €5,068 €3,476 -€1,592 -31.4%
Plant, machinery and equipment 23 €1,948 €701 -€1,246 -64.0%
Furniture and vehicles 24 €3,120 €2,774 -€346 -11.1%
Current assets 29/58 €70,259 €91,518 +€21,259 +30.3%
Amounts receivable within one year 40/41 €43,143 €38,844 -€4,299 -10.0%
Trade receivables 40 €11,072 €10,856 -€215 -1.9%
Other amounts receivable 41 €32,071 €27,987 -€4,084 -12.7%
Cash at bank and in hand 54/58 €27,117 €51,831 +€24,714 +91.1%
Deferred charges and accrued income 490/1 - €844 +€844
Total equity and liabilities 10/49 €75,327 €94,994 +€19,667 +26.1%
Equity 10/15 €66,448 €81,597 +€15,149 +22.8%
Contributions 10/11 €4,000 €4,000 = 0.0%
Reserves 13 - €15,149 +€15,149
Distributable reserves 133 - €15,149 +€15,149
Profit (loss) carried forward 14 €62,448 €62,448 = 0.0%
Amounts payable 17/49 €8,879 €13,397 +€4,518 +50.9%
Amounts payable within one year 42/48 €8,879 €13,397 +€4,518 +50.9%
Trade debts 44 €288 €3,372 +€3,084 +1,071%
Suppliers 440/4 €288 €3,372 +€3,084 +1,071%
Taxes, remuneration and social security 45 €8,591 €10,025 +€1,433 +16.7%
Taxes 450/3 €8,591 €10,025 +€1,433 +16.7%
Remuneration, social security and pensions 62 €0 - =
Depreciation of and write-downs on formation expenses, intangible and tangible fixed assets 630 €1,278 €1,592 +€314 +24.5%
Other operating charges 640/8 €115 €495 +€380 +330%
Gross operating margin 9900 €81,906 €22,997 -€58,909 -71.9%
Operating profit (loss) 9901 €80,512 €20,910 -€59,602 -74.0%
Financial income 75/76B €28 €2,150 +€2,122 +7,633%
Recurring financial income 75 €28 €2,150 +€2,122 +7,633%
Financial charges 65/66B €384 €261 -€122 -31.9%
Recurring financial charges 65 €384 €261 -€122 -31.9%
Profit (loss) for the period before taxes 9903 €80,156 €22,798 -€57,358 -71.6%
Income taxes 67/77 €17,708 €7,649 -€10,059 -56.8%
Profit (loss) for the period 9904 €62,448 €15,149 -€47,299 -75.7%
Profit (loss) for the period to be appropriated 9905 €62,448 €15,149 -€47,299 -75.7%

Value

latest balance sheet 31-12-2025 · indication, not a valuation or advice

Value of the equity

Indication, not a valuation or advice
€179,367 to €234,794

Midpoint €202,461 · 50% capitalised earnings, 50% adjusted equity

Capitalisation rate 12% result over 3 years earnings weight 50%

Worked out with Checked's starting values, not your estimate. Change the assumptions and the value follows.

Adjusted equity €81,597
Capitalised earnings €277,136 to €387,990
Indication €179,367 to €234,794

Adjusted equity

balance sheet 31-12-2025
Equity (10/15)
€81,597
Revaluation of assets
€0
Deferred tax on the revaluation
€0
Other adjustment
€0
Adjusted equity
€81,597

Capitalised earnings

net result for the year (9904)
2025
€15,149
2024
€62,448
Average result
€38,799
Divided by the capitalisation rate
14% / 12% / 10%
Capitalised earnings
€277,136 / €323,325 / €387,990

Limits of the indication

  • Checked holds no market prices or comparable transactions.
  • Anything after the latest accounts and items off the balance sheet (guarantees, leases, disputes) are left out.
  • Checked does not know the real value of buildings, stock and receivables. Enter your own revaluation or adjustment for it.
  • The result is not corrected for the manager's pay. If the company pays less or more than a market salary, the capitalised earnings are too high or too low.
  • The owner's role in the business, synergies for a buyer and the tax consequences of a sale are left out.

For a valuation to base a decision on, go to a company auditor or a certified accountant.

Calculation and sources

Source: filed annual accounts (NBB) and main activity (KBO). The movements compare the financial years ended 31 December 2024 and 31 December 2025. Green is a favourable move for that line, red an unfavourable one. The value is an indication, not a valuation or advice. Prepared on 21 November 2026 via checked.be.